J&J moves FcRn towards a big new therapy area, while Bristol, Merck, Astrazeneca and Daiichi Sankyo await important oncology catalysts.
Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.
Strong mid-stage data seem to show sonelokimab, a Merck KGaA cast-off, beating bigger rivals.
After Calliditas and Travere secure US approvals Novartis doubles down on a rare kidney disease, but what will the FTC say?
Amgen might yet prevail in its attempt to buy Horizon, but the FTC shockwaves will still be felt.
As the FDA cools on the accelerated pathway, could biopharma’s annual approval count take a hit?